Valeant says it's on road to recovery despite cutting forecasts for 2015

Valeant Pharmaceuticals says it's on the road to recovery after taking big financial and PR hits from its association with a controversial U.S.

See Full Article

mail-order pharmacy.

The Quebec-based company expects its revenues and adjusted earnings will increase by double digits in 2016 and its battered share price will once again reflect the fundamentals of its business.

"We have been through a lot," CEO Michael Pearson told investors during a four-hour webcast.

Pearson said he was "pissed" at the "false" allegations about the company from a short seller that drove its share price collapse and prompted some calls for him to be replaced.

"If the board wants to fire me they are welcome to fire me but until they do we're going to get through this thing."

Valeant said the October split from specialty pharmaceutical partner Philidor Rx Services caused a big short-term disruption to its business that will reduce its expectations for the fourth quarter and 2015 as a whole.

However, Pearson said a new distribution deal with a prominent U.S. drugstore chain, Walgreens, is a better arrangement than the one with Philidor, a low-profile company that distributed specialty drugs for Valeant.

Despite cutting prices, Valeant expects it will make more money by gaining access to the 8,000-store network of the largest American pharmacy retailer.

"The opportunity for volume growth is huge," he told analysts.

Pearson said Walgreens was "courageous" for partnering with Valeant given the negative attention heaped on the company in the last few months.

"(But) we both fundamentally believe that this is going to change the industry, it's going to create enormous value for both our shareholders."

Valeant conceded the company, which has been accused of price-gouging for some of its products, has altered its strategy to pursue volume growth by lowering prices and reducing costs.

The deal with Walgreens is forecast to deliver up to US$600 million in annual savings to the U.S. health-care system starting next year after Valeant agreed to cut the prices of several of its drugs as part of the distribution agreement.

Alex Arfaei of BMO Capital Markets said the 2016 revenue guidance of US$12.5 billion to US$12.7 billion is in line with forecasts, but targeted earnings are weaker than predicted.

That "indicates to us that the increase in expected volume from the Walgreens agreement is not enough to offset the loss of more profitable products from the specialty pharmacy business at higher prices, at least in the near term," he wrote in a report.

The Montreal-area company's previously obscure relationship with Philidor and its pricing policies, which are under investigation by U.S. authorities, have contributed to a major decline in the company's stock.

Shares were up nearly eight per cent to $161.26 in Wednesday afternoon trading on the Toronto Stock Exchange.

That's compared to the 52-week low of $92.65 and the $347.84 high in August before its troubles began.

The company faces several U.S. investigations, including at a committee of the U.S. House of Representatives that will be holding a hearing in the new year on increasing prices for medication.

A high-ranking U.S. politician released a letter sent to Valeant that accuses the firm of failing to disclose information as requested and obstructing the congressional investigation.

"Your refusal to provide any documents or witnesses is obstructing this congressional investigation and preventing a full understanding of your company's suspect actions," wrote Elijah Cummings, the committee's ranking Democrat.



Advertisements

Latest Economic News

  • Canadian court approves bid for Trump tower in Toronto

    Economic CTV News
    TORONTO -- A Canadian judge on Thursday approved the sale of the Donald Trump-branded Toronto hotel and condo tower to its main debt holder after no other bids were submitted for the troubled building. Justice GlennHainey of the Ontario Superior Court of Justice approved the $298 million Canadian (US$223 million) "stalking horse" bid from San Diego investment firm JCF Capital ULC. Source
  • Trudeau defends Bombardier aid after executive compensation rose last year

    Economic CTV News
    BRAMPTON, Ont. -- Prime Minister Justin Trudeau is defending his government's decision to provide federal assistance to Bombardier after the company's senior executives saw their compensation rise by nearly 50 per cent last year. After touring a Magna auto parts facility in Brampton, Ont. Source
  • GDP numbers Friday expected to show economy started 2017 strong

    Economic CBC News
    Some economists are revising their forecasts upward for Canadian first-quarter gross domestic product growth, ahead of the Friday release of figures for January. The market consensus for January calls for a growth rate of 0.3 per cent, which would match the December report. Source
  • Brad Wall to meet with Trump cabinet members when he heads to Washington

    Economic CTV News
    REGINA -- Saskatchewan Premier Brad Wall says he has landed meetings with two members of Donald Trump's cabinet next week, including the president's point man on NAFTA. Wall is scheduled to be in Washington and says he will sit down with Secretary of Energy Rick Perry and Secretary of Commerce Wilbur Ross, the man tapped by Trump to deliver on a promise to renegotiate the North American Free Trade Agreement. Source
  • Alberta premier checking to see if Saskatchewan's Wall breaking free-trade deal

    Economic CTV News
    RED DEER, Alta. -- Alberta Premier Rachel Notley says she is looking at whether Saskatchewan's Brad Wall is breaking regional free-trade rules by offering incentives for oil and gas firms to move to his province. Source
  • McDonald's opts for fresh beef, not frozen, for some burgers soon

    Economic CBC News
    Coming soon to McDonald's: Fresh beef. The fast food giant said Thursday that it will swap frozen beef patties for fresh ones in its Quarter Pounder burgers by sometime next year at most of its U.S. Source
  • Environmental groups challenge Keystone XL pipeline approval

    Economic CBC News
    A coalition of environmental groups challenged the U.S. federal permit for the Keystone XL oil pipeline in court on Thursday because they say additional environmental scrutiny is needed. The Sierra Club, Natural Resources Defense Council and other groups say the initial environmental review completed in 2014 is inadequate and outdated, and that it underestimated how much the pipeline would encourage tar sands oil production in Canada. Source
  • Cenovus shares fall in wake of $17.7B oilsands purchase

    Economic CBC News
    Shares in Cenovus Energy were down 11 per cent shortly after markets opened Thursday following its announcement to acquire Canadian assets belonging to Houston-based ConocoPhillips.Cenovus Energy buying most of ConocoPhillips' Canadian assets for $17.7BUnder the $17.7 billion deal, the Calgary-based energy company would take over most of ConocoPhillips's investments in Canada in what is the latest mega oilsands sale by a major foreign oil and gas producer. Source
  • Is Toronto's housing market in a bubble? Not quite, analyst says

    Economic CTV News
    Despite a recent declaration by Bank of Montreal Chief Economist Douglas Porter that Toronto’s red-hot housing market is indeed in a “bubble,” other economists have been hesitant to use the controversial label to describe the city’s current real estate boom. Source
  • CIBC boosts takeover offer for PrivateBancorp to more than $6B

    Economic CBC News
    Shares of Canadian Imperial Bank of Commerce traded lower Thursday after the bank boosted its takeover bid for PrivateBancorp by 20 per cent. Under the terms of a new takeover agreement that has approved by the boards of directors of both firms, the deal values Chicago-based PrivateBancorp at approximately $6.6 billion Cdn, or $60.92 US per share, Source